C-Peptide: What This Test Actually Measures

What C-Peptide Is and Why It Exists

C-peptide (connecting peptide) is a 31-amino-acid chain that gets cut away from proinsulin inside pancreatic beta cells before mature insulin is secreted into the bloodstream. For every single molecule of insulin your body produces, one molecule of C-peptide is released alongside it [1]. That 1:1 molar ratio is the entire reason this test is useful.

Insulin itself is a poor marker of endogenous production for two reasons. First, it has a plasma half-life of only 4 to 6 minutes and is heavily extracted by the liver on first pass, meaning peripheral blood levels fluctuate wildly [2]. Second, exogenous insulin (injected by patients on therapy) is biochemically identical to endogenous insulin in standard immunoassays. C-peptide solves both problems. Its half-life is approximately 30 minutes, giving a much more stable signal, and it is not present in any pharmaceutical insulin formulation [1].

The American Diabetes Association (ADA) 2024 Standards of Care specifically recommend C-peptide measurement when the diabetes type is uncertain, particularly in adults who present with features overlapping between type 1 and type 2 [3]. The Endocrine Society has similarly endorsed C-peptide as the preferred biomarker for quantifying residual beta-cell function in both research and clinical practice [4].

Think of it this way: insulin is the message, but C-peptide is the receipt. It proves the message was sent and tells you exactly how many copies were printed.

How the Test Works in Practice

A fasting serum C-peptide draw is the most common order. The patient fasts for 8 to 12 hours, a standard venipuncture collects serum, and the lab runs a chemiluminescent immunoassay. Results typically return within 24 to 48 hours.

Some clinicians prefer a stimulated C-peptide test, where the patient drinks a mixed-meal tolerance test (MMTT) liquid or receives IV glucagon (1 mg), and blood is drawn at specific intervals (typically 0, 30, 60, 90, and 120 minutes). The MMTT-stimulated C-peptide at 90 minutes is considered the gold standard for assessing beta-cell reserve. The landmark Type 1 Diabetes TrialNet study used MMTT-stimulated C-peptide as its primary endpoint and defined clinically meaningful beta-cell function as a peak stimulated C-peptide of 0.2 nmol/L or higher [5].

A 24-hour urine C-peptide collection is a third option. Because C-peptide is renally cleared, urinary levels integrate total daily insulin production and avoid the pulsatile variability of a single fasting draw [2]. This method is less commonly ordered in routine practice but remains valuable in research settings and for patients where repeated blood draws are impractical.

Regardless of sample type, one critical preanalytic factor matters: renal function. Because C-peptide is cleared by the kidneys, an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m² will artificially raise serum C-peptide levels [6]. Clinicians must interpret results in the context of kidney function or risk misclassifying a patient as having higher beta-cell output than reality.

Normal Ranges and What They Mean

Most reference laboratories report a fasting serum C-peptide range of 0.8 to 3.1 ng/mL (0.26 to 1.03 nmol/L) for adults, though exact cutoffs vary by assay manufacturer [7]. The ADA does not specify a single universal cutoff but has noted that a fasting C-peptide below 0.6 ng/mL (0.2 nmol/L) strongly suggests absolute insulin deficiency consistent with type 1 diabetes [3].

Context changes interpretation completely. A C-peptide of 1.5 ng/mL in a lean adult with normal glucose is reassuring. The same 1.5 ng/mL in a patient with a fasting glucose of 250 mg/dL represents relative beta-cell failure because the pancreas should be producing far more insulin to handle that glucose load. This is why the C-peptide-to-glucose ratio is sometimes calculated, providing a more accurate picture of beta-cell adequacy relative to metabolic demand.

For stimulated testing, a peak C-peptide above 0.6 nmol/L (1.8 ng/mL) after MMTT generally indicates meaningful residual beta-cell function [5]. Below 0.2 nmol/L (0.6 ng/mL), the patient has little to no endogenous insulin production.

The AACE 2023 Comprehensive Diabetes Management Algorithm recommends that clinicians interpret C-peptide alongside hemoglobin A1c, autoantibody status (GAD65, IA-2, ZnT8), and clinical phenotype rather than relying on any single value in isolation [8].

High C-Peptide: Causes and Clinical Significance

An elevated fasting C-peptide (above 3.1 ng/mL in most assays) tells clinicians that beta cells are working overtime. The most common reason is insulin resistance.

In insulin-resistant states such as metabolic syndrome, polycystic ovary syndrome (PCOS), or early type 2 diabetes, tissues respond poorly to insulin. The pancreas compensates by producing more insulin (and therefore more C-peptide). This hyperinsulinemic compensation can persist for years before beta cells begin to fail and glucose levels rise [9]. A 2019 analysis published in Diabetes Care found that individuals in the top quartile of fasting C-peptide had a 2.4-fold increased risk of developing type 2 diabetes over 10 years compared to those in the lowest quartile, independent of fasting glucose [10].

Beyond insulin resistance, elevated C-peptide can signal an insulinoma, a rare insulin-secreting pancreatic neuroendocrine tumor. In suspected factitious hypoglycemia (self-injection of insulin), C-peptide becomes the key differentiator: exogenous insulin suppresses endogenous production, so C-peptide will be low. With an insulinoma, both insulin and C-peptide are high simultaneously [11]. The Endocrine Society Clinical Practice Guideline on hypoglycemia in adults without diabetes recommends measuring C-peptide, insulin, proinsulin, and beta-hydroxybutyrate during a supervised 72-hour fast to confirm or rule out insulinoma [11].

Other causes of elevated C-peptide include renal insufficiency (impaired clearance), Cushing syndrome (cortisol drives insulin resistance), and sulfonylurea use (which directly stimulates beta-cell secretion).

Low C-Peptide: Causes and Clinical Significance

A low fasting C-peptide (below 0.8 ng/mL) indicates that beta cells are producing insufficient insulin. The differential diagnosis depends on the clinical scenario.

Type 1 diabetes is the classic cause. Autoimmune destruction of beta cells progressively eliminates insulin production, and C-peptide drops accordingly. By the time most patients present with symptomatic type 1 diabetes, C-peptide is already well below normal. A 2015 study in Diabetologia (N=1,549) demonstrated that 85% of adults diagnosed with type 1 diabetes had a stimulated C-peptide below 0.2 nmol/L within three years of diagnosis [12].

Latent autoimmune diabetes in adults (LADA) is a slower form of autoimmune beta-cell destruction. These patients are often initially misdiagnosed with type 2 diabetes because they present in adulthood, may be overweight, and have initially adequate C-peptide levels. Over months to years, C-peptide declines, and insulin therapy becomes necessary. The 2020 Expert Consensus from the Immunology of Diabetes Society recommends serial C-peptide monitoring (every 6 to 12 months) in patients with positive GAD65 antibodies to track the rate of beta-cell decline [13].

Advanced type 2 diabetes is another common cause of low C-peptide. After years of compensatory hyperinsulinemia, beta cells undergo exhaustion and apoptosis. A fasting C-peptide below 0.6 ng/mL in a patient with longstanding type 2 diabetes typically indicates that oral medications alone will be insufficient and that exogenous insulin is needed [3].

Exogenous insulin use suppresses endogenous insulin production via negative feedback, and C-peptide drops accordingly. Pancreatectomy or severe chronic pancreatitis can also produce a low C-peptide by directly reducing beta-cell mass.

How to Lower C-Peptide (Reducing Insulin Resistance)

A high C-peptide is a surrogate marker of hyperinsulinemia and insulin resistance. Lowering it means improving insulin sensitivity so the pancreas does not need to overproduce.

Weight loss is the most effective intervention. In the Diabetes Prevention Program (DPP) trial (N=3,234), intensive lifestyle modification (7% body weight loss plus 150 minutes per week of physical activity) reduced the incidence of type 2 diabetes by 58% compared to placebo [14]. Participants who achieved weight loss targets showed significant reductions in fasting insulin and, by extension, C-peptide levels.

GLP-1 receptor agonists like semaglutide reduce C-peptide indirectly by promoting weight loss and directly by improving glucose-dependent insulin secretion efficiency. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo, with corresponding improvements in fasting insulin and HOMA-IR [15].

Metformin reduces hepatic glucose output and modestly improves peripheral insulin sensitivity, lowering the compensatory insulin demand. The DPP trial showed metformin reduced diabetes incidence by 31% versus placebo [14].

Dietary interventions that reduce refined carbohydrate intake and glycemic load decrease the postprandial insulin surge. A 2021 meta-analysis in The American Journal of Clinical Nutrition found that low-glycemic-index diets reduced fasting insulin by 11% compared to high-glycemic-index diets across 54 randomized controlled trials [16].

Exercise independent of weight loss improves insulin sensitivity. Both aerobic and resistance training increase skeletal muscle glucose uptake through GLUT4 translocation. The ADA recommends at least 150 minutes per week of moderate-intensity aerobic exercise plus two sessions of resistance training [3].

How to Raise C-Peptide (Preserving Beta-Cell Function)

In patients with declining C-peptide from autoimmune or progressive beta-cell loss, the goal is to slow destruction and preserve remaining function. This is an area of active research with limited approved therapies.

Teplizumab (Tzield) is the first FDA-approved therapy to delay the onset of stage 3 type 1 diabetes. In the TN-10 trial (N=76), a single 14-day course of teplizumab delayed clinical diabetes onset by a median of 2 years in at-risk individuals with stage 2 type 1 diabetes (two or more autoantibodies plus dysglycemia) [17]. The mechanism involves modulating autoreactive T cells that destroy beta cells, thereby preserving C-peptide production for a longer period.

Tight glycemic control reduces glucotoxicity, which itself accelerates beta-cell apoptosis. The DCCT trial established that intensive insulin therapy in type 1 diabetes preserved higher stimulated C-peptide levels compared to conventional therapy during the first two years of treatment [18]. Patients who maintained residual C-peptide had fewer hypoglycemic episodes and lower A1c values.

Verapamil, a calcium channel blocker, showed unexpected beta-cell protective effects. A randomized controlled trial published in Nature Medicine (N=113) found that adults with recently diagnosed type 1 diabetes who took verapamil 360 mg daily for 12 months had significantly higher stimulated C-peptide levels than placebo (0.65 vs. 0.43 nmol/L, P<0.05) [19]. The proposed mechanism involves reducing expression of thioredoxin-interacting protein (TXNIP), which mediates beta-cell death.

For patients with type 2 diabetes and declining C-peptide, early initiation of insulin therapy (rather than prolonged reliance on sulfonylureas) may preserve beta-cell mass by reducing secretory demand. The ORIGIN trial (N=12,537) found that early basal insulin glargine maintained stable beta-cell function over 6 years [20].

C-Peptide in Specific Clinical Scenarios

Classifying diabetes type in adults. The traditional type 1 versus type 2 distinction is not always straightforward. Up to 10% of adults initially diagnosed with type 2 diabetes actually have LADA [13]. The combination of GAD65 antibody positivity plus a fasting C-peptide below 0.7 nmol/L has a sensitivity exceeding 90% for identifying autoimmune diabetes in adults [12].

Monitoring after bariatric surgery. Roux-en-Y gastric bypass and sleeve gastrectomy dramatically improve insulin sensitivity. Postoperative C-peptide reductions correlate with diabetes remission. A 2020 study in JAMA Surgery (N=1,156) found that patients achieving diabetes remission at 5 years had a mean postoperative fasting C-peptide of 1.8 ng/mL versus 3.4 ng/mL in those who did not [21].

Pregnancy and gestational diabetes. Elevated second-trimester C-peptide predicts adverse neonatal outcomes including macrosomia. The HAPO study (N=23,316) identified a continuous relationship between maternal C-peptide and birth weight above the 90th percentile [22].

Hypoglycemia workup. In a patient presenting with Whipple triad (symptoms, documented low glucose, resolution with glucose), measuring C-peptide during a hypoglycemic episode is essential. A C-peptide above 0.6 ng/mL during hypoglycemia (glucose <55 mg/dL) with simultaneously elevated insulin points toward endogenous hyperinsulinism [11].

When to Order C-Peptide and How Often

The ADA recommends C-peptide testing when diabetes classification is uncertain, when transitioning from oral medications to insulin in type 2 diabetes, and when evaluating unexplained hypoglycemia [3]. It is not part of routine screening for healthy adults.

Serial monitoring makes sense in two populations. Patients with newly diagnosed type 1 diabetes or LADA benefit from C-peptide measurement every 6 to 12 months to track the rate of beta-cell decline and guide treatment decisions [13]. Patients with type 2 diabetes who are failing oral therapy may benefit from a C-peptide check to confirm whether beta-cell reserve justifies adding a sulfonylurea or GLP-1 agonist versus switching to insulin.

Insurance coverage is generally not a barrier. C-peptide is a standard laboratory test covered by most payers when ordered with an appropriate ICD-10 code (E11.65 for type 2 with hyperglycemia, E10.9 for type 1, or E16.1 for hypoglycemia). Out-of-pocket cost without insurance typically ranges from $50 to $150. Fasting samples should be drawn after an 8 to 12 hour overnight fast, with the patient avoiding strenuous exercise the morning of the draw.